{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T17:48:17Z","timestamp":1786297697394,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.msard.2020.102683","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T18:01:44Z","timestamp":1607536904000},"page":"102683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"48","author":[{"given":"Edgar Patricio","family":"Correa-D\u00edaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germaine Eleanor","family":"Torres-Herr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joselyn Elizabeth","family":"Mi\u00f1o Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Paredes-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Caiza-Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102683_bib0001","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study","volume":"263","author":"Annovazzi","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102683_bib0002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.msard.2019.06.013","article-title":"Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city","volume":"34","author":"Ashtari","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102683_bib0003","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.102683_bib0004","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"issue":"9","key":"10.1016\/j.msard.2020.102683_bib0005","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.msard.2020.102683_bib0006","article-title":"Acute optic nerve lesions in first-ever NMOSD-related optic neuritis using conventional brain MRI: A Latin American multicenter study","volume":"46","author":"Carnero Contentti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.msard.2020.102683_bib0007","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","article-title":"Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort","volume":"2020","author":"Carnero Contentti","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2020.102683_bib0008","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"2020","author":"Carnero Contentti","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.msard.2020.102683_bib0009","article-title":"Transverse Myelitis in Systemic Lupus Erythematosus: Clinical Features and Prognostic Factors in a Large Cohort of Latin American Patients","volume":"5","author":"Chiganer","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.msard.2020.102683_bib0010","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jocn.2015.08.033","article-title":"Rapid exacerbation of neuromyelitis optica after rituximab treatment","volume":"26","author":"Dai","year":"2016","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2020.102683_bib0011","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2020.102683_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: A meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.msard.2020.102683_bib0013","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: Creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.102683_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106007","article-title":"Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder","volume":"196","author":"Gomez-Figueroa","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.msard.2020.102683_bib0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin. Med."},{"key":"10.1016\/j.msard.2020.102683_bib0016","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2020.102683_bib0017","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2020.102683_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2018.11.022","article-title":"Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder","volume":"130","author":"Kim","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.msard.2020.102683_bib0019","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab","volume":"316","author":"Li","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102683_bib0020","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jamaneurol.2013.3583","article-title":"Individualized rituximab treatment for neuromyelitis optica spectrum disorders","volume":"70","author":"McKeon","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2020.102683_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.02686","article-title":"The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab","volume":"10","author":"Nicolas","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2020.102683_bib0022","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102683_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101430","article-title":"Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders","volume":"36","author":"Novi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102683_bib0024","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"1028","author":"Poupart","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102683_bib0025","first-page":"14","article-title":"Neuromielitis \u00f3ptica. Actualizaci\u00f3n de los conceptos cl\u00ednicos y fisiopatol\u00f3gicos de la enfermedad","volume":"31","author":"Rojas","year":"2011","journal-title":"Rev. Hosp. Ital. B.Aires"},{"key":"10.1016\/j.msard.2020.102683_bib0026","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","article-title":"B cells in autoimmune and neurodegenerative central nervous system diseases","volume":"20","author":"Sabatino","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.msard.2020.102683_bib0028","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5316\/wjn.v5.i1.39","article-title":"Rituximab in neuromyelitis optica: A review of literature","volume":"5","author":"Wong","year":"2015","journal-title":"World J. Neurol."},{"key":"10.1016\/j.msard.2020.102683_bib0029","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102683_bib0030","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102683_bib0027","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:33Z","timestamp":1761900633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820307574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":30,"alternative-id":["S2211034820307574"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102683","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102683"}}